Antibiotic Prophylaxis in Cataract Surgery: Updated Guidelines

Antibiotic Prophylaxis in Cataract Surgery: Updated Guidelines

Acute endophthalmitis after cataract surgery is rare — a few cases per thousand — and yet it is the complication that keeps every cataract surgeon honest. One case can erase a year of goodwill in a district practice, and a cluster can end a programme. The stakes explain why prophylaxis generates more protocol debate per milligram of drug than almost any other question in ophthalmology: drops or injection, which agent, whose guideline, and what do you do when the evidence and the supply chain disagree.

The good news is that the core evidence base has matured. The ESCRS endophthalmitis study and guideline, large registry analyses, and high-volume Indian data on intracameral moxifloxacin give surgeons a defensible, layered approach. This article summarises the current evidence and translates it into a practical protocol for modern cataract practice — including the volume-surgery environments most Indian surgeons actually work in.

The Evidence That Changed the Field

Three bodies of work anchor contemporary prophylaxis.

The ESCRS randomised study. The European Society of Cataract and Refractive Surgeons' multicentre trial of nearly 14,000 patients demonstrated that intracameral cefuroxime (1 mg in 0.1 mL at wound closure) was associated with an approximately five-fold reduction in postoperative endophthalmitis compared with no intracameral prophylaxis (Barry P et al., Journal of Cataract & Refractive Surgery, 2006). The resulting ESCRS 2013 guideline — the document most often cited in medico-legal contexts — recommends antisepsis with povidone-iodine plus intracameral cefuroxime as the core of prophylaxis, with topical antibiotics as an adjunct rather than the foundation (Barry P, Cordovés L, Gardner S; ESCRS Endophthalmitis Study Group, Journal of Cataract & Refractive Surgery, 2013).

Large-registry confirmation from the United States. Analysis of over two million cataract operations in the IRIS Registry found that intracameral antibiotic injection was associated with a significantly lower endophthalmitis rate than topical-only prophylaxis, in a real-world — not trial — population (Gower EW et al., Ophthalmology, 2017). Registry data cannot randomise away confounding, but two million eyes is a powerful signal.

High-volume Indian experience with moxifloxacin. Where cefuroxime compounding is impractical, Indian surgeons have built an extensive intracameral moxifloxacin evidence base. At the Aravind system, introduction of routine intracameral moxifloxacin across enormous surgical volumes was associated with a significant, sustained reduction in endophthalmitis (Haripriya A et al., Journal of Cataract & Refractive Surgery, 2016). For Indian practice — and for the high-volume models across South Asia, Africa and the Middle East that mirror it — this is arguably the most operationally relevant dataset in existence.

The Non-Negotiable Foundation: Antisepsis

Before any antibiotic enters the discussion, antisepsis deserves its own emphasis, because it remains the highest-certainty intervention in the entire protocol.

• Povidone-iodine 5% applied to the conjunctival sac preoperatively, and 10% to the periocular skin, is the universal standard. No antibiotic regimen compensates for skipped or diluted antisepsis.
• Lid and lash exposure matters: drape to isolate the lash line, the reservoir of Staphylococcus epidermidis that causes most acute postoperative endophthalmitis.
• Do not rely on preoperative topical antibiotics as a substitute. The ESCRS data showed no significant benefit from preoperative levofloxacin drops when intracameral cefuroxime was used — antisepsis plus intracameral delivery does the heavy lifting.
• Antisepsis is process, not product. Contact time, fresh solution, correct concentration and complete lash-line coverage determine efficacy. Build a pre-incision checklist into the theatre time-out so antisepsis is verified aloud, not assumed — the same discipline applied to confirming the correct IOL and patient.

Intracameral Antibiotics: Cefuroxime, Moxifloxacin, Vancomycin

Cefuroxime

The guideline-standard agent where a licensed, ready-to-use formulation is available. Critical practical points: dose accuracy (1 mg/0.1 mL), because dilution errors have caused both toxicity and underdosing, and the well-documented anaphylaxis risk in penicillin-allergic patients, which demands a clear allergy history and a defined alternative pathway.

Moxifloxacin

The pragmatic choice in much of Asia, Africa and the Middle East. Commercially available preservative-free moxifloxacin 0.5% formulations allow direct intracameral injection (typically 0.1 mL, ~500 µg) without pharmacy compounding — removing the dilution-error and contamination risks that accompany improvised preparations. Moxifloxacin also brings fluoroquinolone coverage of Gram-negative organisms that cefuroxime lacks, and avoids the cephalosporin allergy question entirely. The trade-off: moxifloxacin's intracameral use rests on large observational series rather than an ESCRS-scale randomised trial, and fluoroquinolone resistance in ocular flora is a real and growing stewardship concern.

Formulation discipline is non-negotiable here. Only preservative-free moxifloxacin should enter the anterior chamber; preserved formulations risk endothelial toxicity, and "preservative-free" must be verified on the specific product's label and IFU, not assumed from the molecule name. Units adopting intracameral moxifloxacin should write the verification step — product name, preservative status, concentration, expiry — into theatre protocol, because the catastrophic published cases of intracameral toxicity have almost all traced back to the wrong product drawn from the right-looking shelf.

Vancomycin

Reserve discussions only. Given the risk of haemorrhagic occlusive retinal vasculitis associated with intracameral vancomycin and its last-resort status in systemic stewardship, routine prophylactic use is not supported.

Topical, Subconjunctival and Irrigation: Where They Fit

• Postoperative topical fluoroquinolone remains standard adjunctive practice — typically moxifloxacin 0.5% four times daily for one to two weeks — and serves a second duty in surface prophylaxis during the vulnerable early days. (See our post-operative eye drops protocol and the moxifloxacin product page.)
• Subconjunctival injection delivers high anterior-segment levels but adds a procedure, subconjunctival haemorrhage and patient discomfort; most high-volume services have moved to intracameral delivery instead.
• Antibiotics in the irrigating bottle are not recommended: uncontrolled dosing, dilution, and toxicity risk without demonstrated benefit over intracameral bolus.

Why Prevention Dominates Treatment

The prophylaxis debate is asymmetrical because the disease is asymmetrical. Treatment of acute postoperative endophthalmitis — even prompt, protocol-driven intravitreal injection and vitrectomy where indicated — salvages many eyes but restores pre-morbid acuity in only a fraction. Every prophylaxis decision should be weighed against that reality: interventions that reduce incidence from, say, 0.05% to 0.01% prevent a handful of catastrophes per ten thousand cases, which is precisely the scale at which high-volume systems should think.

A related discipline is differentiating infective endophthalmitis from toxic anterior segment syndrome (TASS), the sterile inflammatory cascade triggered by contaminated instrument reprocessing, degraded OVD or imbalanced irrigating solutions. TASS typically presents within 12–48 hours with diffuse corneal oedema and responds to intensive steroids; endophthalmitis more often presents later with vitritis and hypopyon. Misclassification leads either to unnecessary vitrectomy or to catastrophic undertreatment. Prevention here is also systems work: instrument reprocessing audits, single-use consumables where indicated, and verified OVD and irrigating-solution sourcing (ophthalmic viscosurgical devices; irrigation consumables).

Special Situations That Modify the Protocol

• Posterior capsule rupture: the endophthalmitis risk rises several-fold with vitreous loss. Intensify rather than abandon prophylaxis — intracameral antibiotic at closure, and consider a more aggressive postoperative topical course with close day-one review.
• Penicillin/cephalosporin allergy: intracameral cefuroxime carries documented anaphylaxis reports; preservative-free intracameral moxifloxacin is the practical alternative.
• One-eyed patients, immunocompromise, active bleb or ocular surface disease: these warrant the full layered protocol with no shortcuts, earlier review, and a lower threshold for culture if inflammation appears.
• Combined procedures (phaco-trabeculectomy, phaco-vitrectomy): prophylaxis must cover the additional portals of entry; coordinate the regimen with the glaucoma or retina team rather than assuming the cataract protocol suffices.

The "Dropless" Debate

Intracameral antibiotic-steroid injections and punctal depot systems promise to eliminate postoperative drops — attractive for compliance-poor rural populations. The honest reading of current evidence: dropless strategies can work in selected, closely audited settings, but they transfer all perioperative pharmacology into one irreversible intraoperative moment, complicate the management of breakthrough inflammation, and lack the long-run safety record of the layered approach. For most practices, dropless is an interesting option for specific cohorts, not a new standard of care.

Stewardship: The Argument Surgeons Must Take Seriously

Every prophylaxis protocol is also a resistance experiment conducted on the local conjunctival flora. Fluoroquinolone resistance among ocular surface isolates has risen in parallel with perioperative use, and surgeons owe their future patients a disciplined protocol: use intracameral prophylaxis by guideline, use postoperative topical courses at defined duration rather than open-ended, and avoid routine preoperative multi-day antibiotic loading where evidence does not support it. Stewardship is not an argument against prophylaxis — it is an argument for precise prophylaxis.

A Practical, Defensible Protocol

A synthesis consistent with the ESCRS guideline and Indian high-volume practice:

1. Povidone-iodine 5% conjunctival + 10% skin antisepsis, lash-isolating drape, every case.
2. Intracameral antibiotic at wound closure — licensed cefuroxime where available and allergy-permitting; preservative-free moxifloxacin 0.5% as the high-volume alternative. Never extemporaneously diluted multi-use vials.
3. Postoperative topical moxifloxacin 0.5% for a defined 1–2 week course, plus topical steroid ± NSAID per your inflammation protocol (steroid drops; NSAID options).
4. Document the regimen per case, including batch numbers — endophthalmitis clusters are investigated at the level of lots and protocols, and traceability protects the surgeon as much as the patient.
5. Audit your own rate. A unit performing 5,000 cataracts a year should know its endophthalmitis incidence to one decimal place and investigate every case for protocol deviation.

Supply-chain note: prophylaxis fails silently when the preservative-free moxifloxacin or perioperative drops are out of stock and the list proceeds anyway. Contract perioperative pharmaceuticals with the same rigour as IOLs; Oculentis Medical's ophthalmic pharmaceuticals portfolio, including antibiotic drops, is CE Marked, CDSCO-licensed and manufactured under cGMP. Regulatory status varies by country. Before use, consult the Instructions for Use (IFU) supplied with each product.

Frequently Asked Questions

What is the current ESCRS recommendation for endophthalmitis prophylaxis in cataract surgery?

The ESCRS 2013 guideline recommends povidone-iodine antisepsis (5% conjunctival, 10% skin) combined with intracameral cefuroxime 1 mg in 0.1 mL injected at wound closure. Topical antibiotics are adjunctive. The recommendation is based on the ESCRS randomised trial showing an approximately five-fold endophthalmitis reduction.

Is intracameral moxifloxacin as effective as cefuroxime for cataract surgery prophylaxis?

Large observational studies from high-volume Indian centres show intracameral preservative-free moxifloxacin significantly reduces endophthalmitis rates, comparable in effect size to cefuroxime data. It lacks an equivalent randomised trial but avoids compounding errors, offers Gram-negative coverage, and suits penicillin-allergic patients.

Are antibiotic drops alone enough to prevent endophthalmitis after cataract surgery?

Evidence suggests topical antibiotics alone are less protective than intracameral prophylaxis. The IRIS Registry analysis of over two million surgeries and the ESCRS trial both favour intracameral delivery. Best practice combines povidone-iodine antisepsis, intracameral antibiotic and a defined short postoperative topical course.

What dose of intracameral cefuroxime is used in cataract surgery?

The guideline dose is 1 mg in 0.1 mL, injected into the anterior chamber at wound closure. Dose accuracy is critical: preparation errors have caused retinal toxicity at higher concentrations and inadequate prophylaxis when underdosed. Licensed ready-to-use formulations reduce dilution-error risk where available.

Does antibiotic prophylaxis increase antimicrobial resistance on the ocular surface?

Repeated fluoroquinolone exposure selects for resistance in ocular flora, documented in surveillance studies. Mitigation strategies include single intracameral dosing instead of prolonged courses, defined-duration postoperative drops, avoiding unnecessary preoperative loading, and reserving newer agents for treatment rather than routine prophylaxis.

---

Standardise Your Prophylaxis Protocol with Reliable Supply

Oculentis Medical manufactures CE Marked, CDSCO-licensed moxifloxacin eye drops, perioperative antibiotics and steroids under cGMP with full lot traceability — the documentation your endophthalmitis audit trail requires. Download the IFU library or request a product sample for your pharmacy committee evaluation.

---

This article is for educational purposes and is intended for healthcare professionals. It does not constitute medical advice, diagnosis or treatment, and it does not replace clinical judgement, institutional protocols, or the Instructions for Use (IFU) supplied with each product. Clinical outcomes depend on many factors; individual results may vary. Oculentis Medical products are CE Marked and licensed with CDSCO (India); regulatory status varies by country — please contact Oculentis Medical for information specific to your market.